[Androgen receptor-positive triple negative breast cancer: From biology to therapy].

Bulletin du cancer
Thomas Grellety

Abstract

A subgroup of androgen receptor-expressing tumors represents approximately 30 % of all triple negative tumors. The androgen receptor and its signaling pathways have a central biological role in this tumor entity. These triple negative androgen receptor-positive tumors occur in older patients and do not appear to have a better prognosis compared to other triple negative tumors. In addition to androgen receptor-expression, these tumors are genomically characterized by a high frequency of PIK3CA activating mutation. Three clinical trials reported efficacy data for anti-androgens (bicalutamide, abiraterone acetate and enzalutamide) based on strong preclinical rationale. These trials report clinical benefit rates in about one in five patients. These encouraging but still limited results make a case for the identification of predictive response factors and therapeutic combinations to improve response rates. This review will provide an update on the biological and clinical knowledge of this tumoral subgroup that opens the way to non-cytotoxic anti-androgen therapies.

References

Aug 30, 2000·Nature·C M PerouD Botstein
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca DentSteven A Narod
Jan 4, 2008·Histopathology·J S Reis-Filho, A N J Tutt
Nov 10, 2009·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Leo A NiemeierRohit Bhargava
Feb 12, 2010·Nature Reviews. Cancer·Gail P RisbridgerWayne D Tilley
Sep 30, 2010·Nature Reviews. Clinical Oncology·Lisa CareyLuca Gianni
Nov 12, 2010·The New England Journal of Medicine·William D FoulkesJorge S Reis-Filho
Jun 3, 2011·The Journal of Clinical Investigation·Brian D LehmannJennifer A Pietenpol
Jul 26, 2011·Oncogene·M GuedjC Theillet
Sep 18, 2012·The Journal of Steroid Biochemistry and Molecular Biology·K M McNamaraH Sasano
Oct 4, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M Aapro, H Wildiers
Oct 4, 2012·Acta histochemica·Ivana MrklićSnježana Tomić
Oct 31, 2012·Korean Journal of Pathology·Yoon Jin ChaJa Seung Koo
May 15, 2013·Breast Cancer Research : BCR·Jacqueline Lehmann-ChePhilippe Bertheau
Aug 24, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ayca GucalpUNKNOWN Translational Breast Cancer Research Consortium (TBCRC 011)
Oct 12, 2013·The Journal of Pathology·Brian D Lehmann, Jennifer A Pietenpol
Jun 4, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Claudia Arce-SalinasEllen Warner
Apr 8, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H BonnefoiA Gonçalves
Jun 4, 2016·Breast Cancer Research and Treatment·Andrew J RoblesSusan L Mooberry
Dec 21, 2016·International Journal of Biological Sciences·Jiayan LuoXiaoxiang Guan
Feb 6, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ivana Bozovic-SpasojevicChristos Sotiriou
Jun 6, 2017·The New England Journal of Medicine·Mark RobsonPierfranco Conte
Aug 3, 2017·Annals of Surgical Oncology·Ayca Gucalp, Tiffany A Traina
Jan 25, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y BarecheC Sotiriou
Jan 27, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tiffany A TrainaJavier Cortes
May 29, 2018·British Journal of Cancer·Lironne WeinSherene Loi
Oct 26, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Thomas GrelletyBruno Cardinaud
Feb 1, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·I Vaz-LuisN U Lin
Sep 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K GelmonS Verma

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.